DBS denied for missing prior authorization by Blue Cross Blue Shield?
If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Blue Cross Blue Shield's specific coverage criteria for dbs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Blue Cross Blue Shield angle on DBS
## Why BCBS Issues Prior-Auth-Required Denials for Deep Brain Stimulation (DBS)
Deep brain stimulation is consistently listed as a procedure requiring prior authorization by BCBS because it is a high-cost, elective neurosurgical intervention with specific clinical criteria that must be verified before the procedure. A prior-auth-required denial almost always means one of three things: (1) prior authorization was not obtained before the procedure was performed; (2) a prior authorization request was submitted but is pending review; or (3) a prior authorization was obtained but the submitted claim does not match the authorized service in a material way (different device, different date, different laterality, or different procedure code). Each of these scenarios has a different appeal path.
## Why This Denial Is Appealable
For retrospective denials (procedure already performed without prior auth), most BCBS plans allow a post-service appeal in which the clinical team can demonstrate that the procedure was medically necessary and met all criteria that would have been required for approval. Courts and regulators have generally held that insurers cannot use procedural prior-authorization failures to deny coverage for care that was genuinely medically necessary and would have been approved. For pending or mis-matched authorizations, the resolution is often administrative rather than clinical.
## Federal Appeal Framework
- Internal appeal: File within the timeframe on your denial notice (often 180 days for post-service claims). BCBS must respond within 60 days for post-service appeals.
- Retrospective review request: Simultaneously request a retrospective medical-necessity review, framing the appeal as a demonstration that the procedure met all prior-authorization criteria.
- Expedited appeal: If care is ongoing or urgently needed, request expedited review; BCBS must respond within 72 hours.
- External review (ACA §2719 / ERISA §503): After final internal denial, request independent external review within approximately four months. External reviewers can overturn procedural denials when the underlying care was medically necessary.
## Documentation to Gather
1. Prior authorization records — any PA request submissions, reference numbers, approval letters, or correspondence with BCBS regarding the procedure. 2. Clinical records supporting medical necessity — specialist evaluation, diagnosis confirmation, prior treatment history, and symptom-severity documentation that would have supported PA approval. 3. Procedure records — operative report, device implant documentation, and any facility records confirming what was performed. 4. Prescriber letter — your neurosurgeon should write a letter explaining the clinical urgency or necessity of the procedure and confirming it met BCBS's standard prior-authorization criteria. 5. Timeline documentation — if authorization was not obtained due to scheduling, urgency, or administrative error, document the timeline clearly.
## Criteria-Mapping Structure
Obtain BCBS's current prior-authorization requirements and medical policy for DBS. Demonstrate retrospectively that each criterion was met:
| PA Criterion | Retrospective Evidence | |---|---| | Diagnosis meets covered indication | [specialist diagnosis note, date] | | Prior medical therapy documented | [medication history, outcomes] | | DBS candidacy evaluation | [specialist evaluation, date] | | Surgeon/facility qualifications | [credentials documentation] | | Procedure matches FDA-approved use | [operative report, device records] |
A retrospective appeal that mirrors the prior-authorization checklist — point by point — gives the reviewer a clear path to approval and avoids the common mistake of submitting records without connecting them to the specific denial criteria.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied for missing prior authorization of 17ohp Compounded
- Blue Cross Blue Shield denied for missing prior authorization of AAT Augmentation
- Blue Cross Blue Shield denied for missing prior authorization of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied for missing prior authorization of Anti Cd 20 Ocrevus